Skip to Main Content
1-877-YALEMDS
SpecialistsFact SheetsDepartmentsClinical TrialsNewsPatient ToolsFor Medical Professionals
1-877-YALEMDS
  • Search
  • Clinical Trials
  • Scott Gettinger

Clinical Trials

    • Cancer(5)
  • Lung Cancer

    Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer

    • Lung Cancer

      Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

      • Lung Cancer

        LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

        • Lung Cancer

          Phase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

          • Lung Cancer

            Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

            • About Us
            • Contact Us
            • Donate
            • Referring Doctors
            • Clinical Keywords

            333 Cedar St.

            New Haven, CT 06510

            • Yale School of Medicine
            • Yale University
            • Terms & Privacy Policies
            • Accessibility at YSM
            • Patient Rights
            • HIPAA at Yale
            • Non-discrimination Statement
            Copyright 2025 Yale Medicine